Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Mei Yamada"'
Autor:
Kotaro Sakamoto, Seigo Iwata, Zihao Jin, Lu Chen, Tatsunori Miyaoka, Mei Yamada, Kaiga Katahira, Rei Yokoyama, Ami Ono, Satoshi Asano, Kotaro Tanimoto, Rika Ishimura, Shinsaku Nakagawa, Takatsugu Hirokawa, Yukio Ago, Eijiro Miyako
Publikováno v:
JACS Au, Vol 4, Iss 8, Pp 2811-2817 (2024)
Externí odkaz:
https://doaj.org/article/aa113cdf44a34434ada51d6d3b16c4ca
Autor:
Mei Yamada, Joto Yoshimoto, Tetsuya Maeda, Sho Ishii, Mikiya Kishi, Takashi Taguchi, Hidetoshi Morita
Publikováno v:
Food Science & Nutrition, Vol 11, Iss 8, Pp 4572-4582 (2023)
Abstract Legumes contain dietary fiber and resistant starch, which are beneficial to the intestinal environment. Here, we investigated the effects of yellow pea noodle consumption on the gut microbiota and fecal metabolome of healthy individuals. Thi
Externí odkaz:
https://doaj.org/article/0e812ab68d9b4f299241167e0baed18b
Publikováno v:
Frontiers in Nutrition, Vol 9 (2022)
This study aims to verify the effects of “legume-based noodles” as a staple food for lunch, specifically: blood glucose, cognitive function tests, Kansei value, work questionnaires, typing, and body weight. The experiment is divided into two grou
Externí odkaz:
https://doaj.org/article/30f3cfe7fe11493181553d3daa3d95ef
Autor:
Kotaro Sakamoto, Lu Chen, Tatsunori Miyaoka, Mei Yamada, Teruaki Masutani, Kenji Ishimoto, Nobumasa Hino, Shinsaku Nakagawa, Satoshi Asano, Yukio Ago
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Worldwide, more than 20 million people suffer from schizophrenia, but effective and definitive new therapeutic drugs/treatments have not been established. Vasoactive intestinal peptide receptor 2 (VIPR2) might be an attractive drug target for the tre
Externí odkaz:
https://doaj.org/article/a48f0731bf1640b887ab23400b1a5cfb
Autor:
Tetsuo Yano, Teppei Ito, Yuya Kanehira, Mei Yamada, Hiromi Kimura-Suda, Hirotaka Wagatsuma, Daisuke Inoue
Publikováno v:
Bone Reports, Vol 14, Iss , Pp 101061- (2021)
Combination therapy of active vitamin D3 with some bisphosphonates (BPs) has been reported to be clinically beneficial. However, combination therapy of eldecalcitol (ELD) with BP has to date not been validated as to whether it is beneficial in the cl
Externí odkaz:
https://doaj.org/article/13b7df71464540c78add0adc12dd5976
Autor:
Shuto Takeuchi, Takuya Kawanai, Ryosuke Yamauchi, Lu Chen, Tatsunori Miyaoka, Mei Yamada, Satoshi Asano, Atsuko Hayata-Takano, Takanobu Nakazawa, Koji Yano, Naotaka Horiguchi, Shinsaku Nakagawa, Kazuhiro Takuma, James A. Waschek, Hitoshi Hashimoto, Yukio Ago
Publikováno v:
Frontiers in Neuroscience, Vol 14 (2020)
Clinical studies have shown that microduplications at 7q36.3, containing VIPR2, confer significant risk for schizophrenia and autism spectrum disorder (ASD). VIPR2 gene encodes the VPAC2 receptor for vasoactive intestinal peptide (VIP) and pituitary
Externí odkaz:
https://doaj.org/article/5aacf9b8b65c485995cafa3a29a95fc0
Publikováno v:
Frontiers in nutrition. 9
This study aims to verify the effects of “legume-based noodles” as a staple food for lunch, specifically: blood glucose, cognitive function tests, Kansei value, work questionnaires, typing, and body weight. The experiment is divided into two grou
Autor:
Teppei Ito, Mei Yamada, Hiromi Kimura-Suda, Yuya Kanehira, Hirotaka Wagatsuma, Tetsuo Yano, Daisuke Inoue
Publikováno v:
Bone Reports
Bone Reports, Vol 14, Iss, Pp 101061-(2021)
Bone Reports, Vol 14, Iss, Pp 101061-(2021)
Combination therapy of active vitamin D3 with some bisphosphonates (BPs) has been reported to be clinically beneficial. However, combination therapy of eldecalcitol (ELD) with BP has to date not been validated as to whether it is beneficial in the cl
Publikováno v:
Calcified Tissue International
Teriparatide (TPTD), a recombinant human parathyroid hormone N-terminal fragment (1–34), is a widely used bone anabolic drug for osteoporosis. Sequential treatment with antiresorptives such as bisphosphonates after TPTD discontinuation is generally
Publikováno v:
Journal of Bone and Mineral Metabolism. 32:653-659
Clinical evidence suggests that, compared with alendronate, risedronate reduces fracture risk faster and more potently, with less bone mass gain. We tested the hypothesis that risedronate improves bone quality faster than alendronate using calcium-de